Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Launched by FUDAN UNIVERSITY · May 3, 2024

Keywords

ClinConnect Summary

The FUSCC-Thymic 3 clinical trial is studying how effective a type of chemotherapy is for patients with thymic carcinoma after they have had surgery to remove the tumor. The main goals are to find out if adding chemotherapy helps prevent the cancer from coming back and whether patients can tolerate the treatment well. Participants in the trial will receive either radiation therapy alone or radiation therapy combined with four cycles of chemotherapy using three medications: paclitaxel, cisplatin, and 5-FU.

To qualify for this trial, participants must be between 18 and 75 years old, have recently undergone surgery for thymic cancer, and have had their cancer completely removed. They also need to be in good health overall, without serious issues affecting their blood, heart, lungs, or other organs. If eligible, participants will have follow-up visits every three months for the first two years to monitor their health and response to treatment. This trial is currently recruiting patients of all genders and offers an opportunity to contribute to important research that may improve treatment options for thymic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntarily participate and sign an informed consent form in writing;
• • 2. Age range from 18 to 75 years old, regardless of gender;
• • 3. Within 3 months after the surgery is completed;
• • 4. Histologically diagnosed with thymic cancer;
• • 5. Complete resection based on surgical records, pathological reports, and postoperative imaging;
• • 6. Masaoka stage: I-III
• • 7. No severe hematopoietic function, heart, lung, liver, kidney dysfunction, or immune deficiency;
• • 8. White blood cells ≥ 3 × 109/L; Neutrophils ≥ 1.5 × 109/L; Hemoglobin ≥ 10 g/dL; Platelets ≥ 100 × 109/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)/ALT (SGPT) ≤ 2.5 times the upper limit of normal value; Creatinine ≤ 1.5 times the upper limit of normal value;
• Exclusion Criteria:
• • 1. Having a second primary tumor (excluding cured non malignant melanoma of the skin, papillary thyroid carcinoma, stage I seminomatoma, cervical carcinoma in situ, or other curable tumors that have been tumor free for more than 3 years after treatment);
• • 2. Symptomatic coronary heart disease, left heart failure, uncontrollable seizures, or loss of self-awareness due to mental illness;
• • 3. Pregnancy and lactation period;
• • 4. Patients with drug addiction, chronic alcoholism and AIDS;
• • 5. Researchers believe that participants are not suitable for this experiment.